APO Research
Talk to an analyst

APO RESEARCH · REPORT

Amyotrophic Lateral Sclerosis (ALS)

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Amyotrophic Lateral Sclerosis (ALS) Market Analysis and Forecast 2026-2032

20 December 2025197 pages

Choose your research edition.

Industry ResearchAmyotrophic Lateral Sclerosis (ALS) Industry Research Report 2026117 pages · $2,950 USDIndustry Growth & TrendsGlobal Amyotrophic Lateral Sclerosis (ALS) Industry Growth and Trends Forecast to 203297 pages · $3,450 USDMarket StructureGlobal Amyotrophic Lateral Sclerosis (ALS) Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032184 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Amyotrophic Lateral Sclerosis (ALS) Market Outlook and Growth Opportunities 2026192 pages · $4,250 USDMarket Analysis & ForecastGlobal Amyotrophic Lateral Sclerosis (ALS) Market Analysis and Forecast 2026-2032197 pages · $4,950 USD

Market perspective

The global Amyotrophic Lateral Sclerosis (ALS) market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for Amyotrophic Lateral Sclerosis (ALS) is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Amyotrophic Lateral Sclerosis (ALS) is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Amyotrophic Lateral Sclerosis (ALS) is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Amyotrophic Lateral Sclerosis (ALS) is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global manufacturers of Amyotrophic Lateral Sclerosis (ALS) include Sun Pharma, Sanofi, Lunan Pharma, Mylan Pharma, Mitsubishi Tanabe Pharma, Glemark Generics, Covis Pharma and Apotex, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Amyotrophic Lateral Sclerosis (ALS), sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Amyotrophic Lateral Sclerosis (ALS), also provides the sales of main regions and countries. Of the upcoming market potential for Amyotrophic Lateral Sclerosis (ALS), and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Amyotrophic Lateral Sclerosis (ALS) sales, revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Amyotrophic Lateral Sclerosis (ALS) market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2021 to 2032. Evaluation and forecast the market size for Amyotrophic Lateral Sclerosis (ALS) sales, projected growth trends, production technology, application and end-user industry.

Amyotrophic Lateral Sclerosis (ALS) Segment by Company

Sun Pharma

Sanofi

Lunan Pharma

Mylan Pharma

Mitsubishi Tanabe Pharma

Glemark Generics

Covis Pharma

Apotex

Amyotrophic Lateral Sclerosis (ALS) Segment by Type

Riluzole

Edaravone (Radicava)

Other

Amyotrophic Lateral Sclerosis (ALS) Segment by Application

Hospital

Drugs Store

Other

Amyotrophic Lateral Sclerosis (ALS) Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Amyotrophic Lateral Sclerosis (ALS) market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Amyotrophic Lateral Sclerosis (ALS) and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Amyotrophic Lateral Sclerosis (ALS).

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Sales (consumption), revenue of Amyotrophic Lateral Sclerosis (ALS) in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.

Chapter 4: Detailed analysis of Amyotrophic Lateral Sclerosis (ALS) manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Amyotrophic Lateral Sclerosis (ALS) sales, revenue, price, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, sales, and revenue for each segment.

Chapter 9: Europe by type, by application and by country, sales, and revenue for each segment.

Chapter 10: China type, by application, sales, and revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, sales, and revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, sales, and revenue for each segment.

Chapter 13: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.

Chapter 14: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Amyotrophic Lateral Sclerosis (ALS) Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Riluzole Major Manufacturers Table 3. Edaravone (Radicava) Major Manufacturers Table 4. Other Major Manufacturers Table 5. Global Amyotrophic Lateral Sclerosis (ALS) Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 6. Hospital Major Manufacturers Table 7. Drugs Store Major Manufacturers Table 8. Other Major Manufacturers Table 9. Amyotrophic Lateral Sclerosis (ALS) Industry Trends Table 10. Amyotrophic Lateral Sclerosis (ALS) Industry Drivers Table 11. Amyotrophic Lateral Sclerosis (ALS) Industry Opportunities and Challenges Table 12. Amyotrophic Lateral Sclerosis (ALS) Industry Restraints Table 13. Global Amyotrophic Lateral Sclerosis (ALS) Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 14. Global Amyotrophic Lateral Sclerosis (ALS) Revenue by Region (2021-2026) & (US$ Million) Table 15. Global Amyotrophic Lateral Sclerosis (ALS) Revenue by Region (2027-2032) & (US$ Million) Table 16. Global Amyotrophic Lateral Sclerosis (ALS) Revenue Market Share by Region (2021-2026) Table 17. Global Amyotrophic Lateral Sclerosis (ALS) Revenue Market Share by Region (2027-2032) Table 18. Global Amyotrophic Lateral Sclerosis (ALS) Sales Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (k units) Table 19. Global Amyotrophic Lateral Sclerosis (ALS) Sales by Region (2021-2026) & (k units) Table 20. Global Amyotrophic Lateral Sclerosis (ALS) Sales by Region (2027-2032) & (k units) Table 21. Global Amyotrophic Lateral Sclerosis (ALS) Sales Market Share by Region (2021-2026) Table 22. Global Amyotrophic Lateral Sclerosis (ALS) Sales Market Share by Region (2027-2032) Table 23. Global Amyotrophic Lateral Sclerosis (ALS) Revenue by Manufacturers (US$ Million) & (2021-2026) Table 24. Global Amyotrophic Lateral Sclerosis (ALS) Revenue Market Share by Manufacturers (2021-2026) Table 25. Global Amyotrophic Lateral Sclerosis (ALS) Sales by Manufacturers (US$ Million) & (2021-2026) Table 26. Global Amyotrophic Lateral Sclerosis (ALS) Sales Market Share by Manufacturers (2021-2026) Table 27. Global Amyotrophic Lateral Sclerosis (ALS) Sales Price (US$/unit) of Manufacturers (2021-2026) Table 28. Global Amyotrophic Lateral Sclerosis (ALS) Key Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 29. Global Amyotrophic Lateral Sclerosis (ALS) Key Manufacturers Manufacturing Sites & Headquarters Table 30. Global Amyotrophic Lateral Sclerosis (ALS) Manufacturers, Product Type & Application Table 31. Global Amyotrophic Lateral Sclerosis (ALS) Manufacturers' Establishment Date Table 32. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 33. Global Amyotrophic Lateral Sclerosis (ALS) by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 34. Global Amyotrophic Lateral Sclerosis (ALS) Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 35. Global Amyotrophic Lateral Sclerosis (ALS) Revenue by Type (2021-2026) & (US$ Million) Table 36. Global Amyotrophic Lateral Sclerosis (ALS) Revenue by Type (2027-2032) & (US$ Million) Table 37. Global Amyotrophic Lateral Sclerosis (ALS) Revenue Market Share by Type (2021-2026) Table 38. Global Amyotrophic Lateral Sclerosis (ALS) Revenue Market Share by Type (2027-2032) Table 39. Global Amyotrophic Lateral Sclerosis (ALS) Sales by Type 2021 VS 2025 VS 2032 (k units) Table 40. Global Amyotrophic Lateral Sclerosis (ALS) Sales by Type (2021-2026) & (k units) Table 41. Global Amyotrophic Lateral Sclerosis (ALS) Sales by Type (2027-2032) & (k units) Table 42. Global Amyotrophic Lateral Sclerosis (ALS) Sales Market Share by Type (2021-2026) Table 43. Global Amyotrophic Lateral Sclerosis (ALS) Sales Market Share by Type (2027-2032) Table 44. Global Amyotrophic Lateral Sclerosis (ALS) Price by Type (2021-2026) & (US$/unit) Table 45. Global Amyotrophic Lateral Sclerosis (ALS) Price by Type (2027-2032) & (US$/unit) Table 46. Global Amyotrophic Lateral Sclerosis (ALS) Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 47. Global Amyotrophic Lateral Sclerosis (ALS) Revenue by Application (2021-2026) & (US$ Million) Table 48. Global Amyotrophic Lateral Sclerosis (ALS) Revenue by Application (2027-2032) & (US$ Million) Table 49. Global Amyotrophic Lateral Sclerosis (ALS) Revenue Market Share by Application (2021-2026) Table 50. Global Amyotrophic Lateral Sclerosis (ALS) Revenue Market Share by Application (2027-2032) Table 51. Global Amyotrophic Lateral Sclerosis (ALS) Sales by Application 2021 VS 2025 VS 2032 (k units) Table 52. Global Amyotrophic Lateral Sclerosis (ALS) Sales by Application (2021-2026) & (k units) Table 53. Global Amyotrophic Lateral Sclerosis (ALS) Sales by Application (2027-2032) & (k units) Table 54. Global Amyotrophic Lateral Sclerosis (ALS) Sales Market Share by Application (2021-2026) Table 55. Global Amyotrophic Lateral Sclerosis (ALS) Sales Market Share by Application (2027-2032) Table 56. Global Amyotrophic Lateral Sclerosis (ALS) Price by Application (2021-2026) & (US$/unit) Table 57. Global Amyotrophic Lateral Sclerosis (ALS) Price by Application (2027-2032) & (US$/unit) Table 58. Sun Pharma Company Information Table 59. Sun Pharma Business Overview Table 60. Sun Pharma Amyotrophic Lateral Sclerosis (ALS) Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 61. Sun Pharma Amyotrophic Lateral Sclerosis (ALS) Product Portfolio Table 62. Sun Pharma Recent Development Table 63. Sanofi Company Information Table 64. Sanofi Business Overview Table 65. Sanofi Amyotrophic Lateral Sclerosis (ALS) Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 66. Sanofi Amyotrophic Lateral Sclerosis (ALS) Product Portfolio Table 67. Sanofi Recent Development Table 68. Lunan Pharma Company Information Table 69. Lunan Pharma Business Overview Table 70. Lunan Pharma Amyotrophic Lateral Sclerosis (ALS) Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 71. Lunan Pharma Amyotrophic Lateral Sclerosis (ALS) Product Portfolio Table 72. Lunan Pharma Recent Development Table 73. Mylan Pharma Company Information Table 74. Mylan Pharma Business Overview Table 75. Mylan Pharma Amyotrophic Lateral Sclerosis (ALS) Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 76. Mylan Pharma Amyotrophic Lateral Sclerosis (ALS) Product Portfolio Table 77. Mylan Pharma Recent Development Table 78. Mitsubishi Tanabe Pharma Company Information Table 79. Mitsubishi Tanabe Pharma Business Overview Table 80. Mitsubishi Tanabe Pharma Amyotrophic Lateral Sclerosis (ALS) Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 81. Mitsubishi Tanabe Pharma Amyotrophic Lateral Sclerosis (ALS) Product Portfolio Table 82. Mitsubishi Tanabe Pharma Recent Development Table 83. Glemark Generics Company Information Table 84. Glemark Generics Business Overview Table 85. Glemark Generics Amyotrophic Lateral Sclerosis (ALS) Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 86. Glemark Generics Amyotrophic Lateral Sclerosis (ALS) Product Portfolio Table 87. Glemark Generics Recent Development Table 88. Covis Pharma Company Information Table 89. Covis Pharma Business Overview Table 90. Covis Pharma Amyotrophic Lateral Sclerosis (ALS) Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 91. Covis Pharma Amyotrophic Lateral Sclerosis (ALS) Product Portfolio Table 92. Covis Pharma Recent Development Table 93. Apotex Company Information Table 94. Apotex Business Overview Table 95. Apotex Amyotrophic Lateral Sclerosis (ALS) Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 96. Apotex Amyotrophic Lateral Sclerosis (ALS) Product Portfolio Table 97. Apotex Recent Development Table 98. North America Amyotrophic Lateral Sclerosis (ALS) Revenue by Type (2021-2026) & (US$ Million) Table 99. North America Amyotrophic Lateral Sclerosis (ALS) Revenue by Type (2027-2032) & (US$ Million) Table 100. North America Amyotrophic Lateral Sclerosis (ALS) Sales by Type (2021-2026) & (k units) Table 101. North America Amyotrophic Lateral Sclerosis (ALS) Sales by Type (2027-2032) & (k units) Table 102. North America Amyotrophic Lateral Sclerosis (ALS) Sales Price by Type (2021-2026) & (US$/unit) Table 103. North America Amyotrophic Lateral Sclerosis (ALS) Sales Price by Type (2027-2032) & (US$/unit) Table 104. North America Amyotrophic Lateral Sclerosis (ALS) Revenue by Application (2021-2026) & (US$ Million) Table 105. North America Amyotrophic Lateral Sclerosis (ALS) Revenue by Application (2027-2032) & (US$ Million) Table 106. North America Amyotrophic Lateral Sclerosis (ALS) Sales by Application (2021-2026) & (k units) Table 107. North America Amyotrophic Lateral Sclerosis (ALS) Sales by Application (2027-2032) & (k units) Table 108. North America Amyotrophic Lateral Sclerosis (ALS) Sales Price by Application (2021-2026) & (US$/unit) Table 109. North America Amyotrophic Lateral Sclerosis (ALS) Sales Price by Application (2027-2032) & (US$/unit) Table 110. North America Amyotrophic Lateral Sclerosis (ALS) Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 111. North America Amyotrophic Lateral Sclerosis (ALS) Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 112. North America Amyotrophic Lateral Sclerosis (ALS) Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 113. North America Amyotrophic Lateral Sclerosis (ALS) Sales by Country (2021 VS 2025 VS 2032) & (k units) Table 114. North America Amyotrophic Lateral Sclerosis (ALS) Sales by Country (2021-2026) & (k units) Table 115. North America Amyotrophic Lateral Sclerosis (ALS) Sales by Country (2027-2032) & (k units) Table 116. North America Amyotrophic Lateral Sclerosis (ALS) Sales Price by Country (2021-2026) & (US$/unit) Table 117. North America Amyotrophic Lateral Sclerosis (ALS) Sales Price by Country (2027-2032) & (US$/unit) Table 118. United States Amyotrophic Lateral Sclerosis (ALS) Revenue (2021-2032) & (US$ Million) Table 119. Canada Amyotrophic Lateral Sclerosis (ALS) Revenue (2021-2032) & (US$ Million) Table 120. Mexico Amyotrophic Lateral Sclerosis (ALS) Revenue (2021-2032) & (US$ Million) Table 121. Europe Amyotrophic Lateral Sclerosis (ALS) Revenue by Type (2021-2026) & (US$ Million) Table 122. Europe Amyotrophic Lateral Sclerosis (ALS) Revenue by Type (2027-2032) & (US$ Million) Table 123. Europe Amyotrophic Lateral Sclerosis (ALS) Sales by Type (2021-2026) & (k units) Table 124. Europe Amyotrophic Lateral Sclerosis (ALS) Sales by Type (2027-2032) & (k units) Table 125. Europe Amyotrophic Lateral Sclerosis (ALS) Sales Price by Type (2021-2026) & (US$/unit) Table 126. Europe Amyotrophic Lateral Sclerosis (ALS) Sales Price by Type (2027-2032) & (US$/unit) Table 127. Europe Amyotrophic Lateral Sclerosis (ALS) Revenue by Application (2021-2026) & (US$ Million) Table 128. Europe Amyotrophic Lateral Sclerosis (ALS) Revenue by Application (2027-2032) & (US$ Million) Table 129. Europe Amyotrophic Lateral Sclerosis (ALS) Sales by Application (2021-2026) & (k units) Table 130. Europe Amyotrophic Lateral Sclerosis (ALS) Sales by Application (2027-2032) & (k units) Table 131. Europe Amyotrophic Lateral Sclerosis (ALS) Sales Price by Application (2021-2026) & (US$/unit) Table 132. Europe Amyotrophic Lateral Sclerosis (ALS) Sales Price by Application (2027-2032) & (US$/unit) Table 133. Europe Amyotrophic Lateral Sclerosis (ALS) Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 134. Europe Amyotrophic Lateral Sclerosis (ALS) Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 135. Europe Amyotrophic Lateral Sclerosis (ALS) Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 136. Europe Amyotrophic Lateral Sclerosis (ALS) Sales by Country (2021 VS 2025 VS 2032) & (k units) Table 137. Europe Amyotrophic Lateral Sclerosis (ALS) Sales by Country (2021-2026) & (k units) Table 138. Europe Amyotrophic Lateral Sclerosis (ALS) Sales by Country (2027-2032) & (k units) Table 139. Europe Amyotrophic Lateral Sclerosis (ALS) Sales Price by Country (2021-2026) & (US$/unit) Table 140. Europe Amyotrophic Lateral Sclerosis (ALS) Sales Price by Country (2027-2032) & (US$/unit) Table 141. Germany Amyotrophic Lateral Sclerosis (ALS) Revenue (2021-2032) & (US$ Million) Table 142. France Amyotrophic Lateral Sclerosis (ALS) Revenue (2021-2032) & (US$ Million) Table 143. U.K. Amyotrophic Lateral Sclerosis (ALS) Revenue (2021-2032) & (US$ Million) Table 144. Italy Amyotrophic Lateral Sclerosis (ALS) Revenue (2021-2032) & (US$ Million) Table 145. Russia Amyotrophic Lateral Sclerosis (ALS) Revenue (2021-2032) & (US$ Million) Table 146. Spain Amyotrophic Lateral Sclerosis (ALS) Revenue (2021-2032) & (US$ Million) Table 147. Netherlands Amyotrophic Lateral Sclerosis (ALS) Revenue (2021-2032) & (US$ Million) Table 148. Switzerland Amyotrophic Lateral Sclerosis (ALS) Revenue (2021-2032) & (US$ Million) Table 149. Sweden Amyotrophic Lateral Sclerosis (ALS) Revenue (2021-2032) & (US$ Million) Table 150. Poland Amyotrophic Lateral Sclerosis (ALS) Revenue (2021-2032) & (US$ Million) Table 151. China Amyotrophic Lateral Sclerosis (ALS) Revenue by Type (2021-2026) & (US$ Million) Table 152. China Amyotrophic Lateral Sclerosis (ALS) Revenue by Type (2027-2032) & (US$ Million) Table 153. China Amyotrophic Lateral Sclerosis (ALS) Sales by Type (2021-2026) & (k units) Table 154. China Amyotrophic Lateral Sclerosis (ALS) Sales by Type (2027-2032) & (k units) Table 155. China Amyotrophic Lateral Sclerosis (ALS) Sales Price by Type (2021-2026) & (US$/unit) Table 156. China Amyotrophic Lateral Sclerosis (ALS) Sales Price by Type (2027-2032) & (US$/unit) Table 157. China Amyotrophic Lateral Sclerosis (ALS) Revenue by Application (2021-2026) & (US$ Million) Table 158. China Amyotrophic Lateral Sclerosis (ALS) Revenue by Application (2027-2032) & (US$ Million) Table 159. China Amyotrophic Lateral Sclerosis (ALS) Sales by Application (2021-2026) & (k units) Table 160. China Amyotrophic Lateral Sclerosis (ALS) Sales by Application (2027-2032) & (k units) Table 161. China Amyotrophic Lateral Sclerosis (ALS) Sales Price by Application (2021-2026) & (US$/unit) Table 162. China Amyotrophic Lateral Sclerosis (ALS) Sales Price by Application (2027-2032) & (US$/unit) Table 163. Asia Amyotrophic Lateral Sclerosis (ALS) Revenue by Type (2021-2026) & (US$ Million) Table 164. Asia Amyotrophic Lateral Sclerosis (ALS) Revenue by Type (2027-2032) & (US$ Million) Table 165. Asia Amyotrophic Lateral Sclerosis (ALS) Sales by Type (2021-2026) & (k units) Table 166. Asia Amyotrophic Lateral Sclerosis (ALS) Sales by Type (2027-2032) & (k units) Table 167. Asia Amyotrophic Lateral Sclerosis (ALS) Sales Price by Type (2021-2026) & (US$/unit) Table 168. Asia Amyotrophic Lateral Sclerosis (ALS) Sales Price by Type (2027-2032) & (US$/unit) Table 169. Asia Amyotrophic Lateral Sclerosis (ALS) Revenue by Application (2021-2026) & (US$ Million) Table 170. Asia Amyotrophic Lateral Sclerosis (ALS) Revenue by Application (2027-2032) & (US$ Million) Table 171. Asia Amyotrophic Lateral Sclerosis (ALS) Sales by Application (2021-2026) & (k units) Table 172. Asia Amyotrophic Lateral Sclerosis (ALS) Sales by Application (2027-2032) & (k units) Table 173. Asia Amyotrophic Lateral Sclerosis (ALS) Sales Price by Application (2021-2026) & (US$/unit) Table 174. Asia Amyotrophic Lateral Sclerosis (ALS) Sales Price by Application (2027-2032) & (US$/unit) Table 175. Asia Amyotrophic Lateral Sclerosis (ALS) Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 176. Asia Amyotrophic Lateral Sclerosis (ALS) Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 177. Asia Amyotrophic Lateral Sclerosis (ALS) Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 178. Asia Amyotrophic Lateral Sclerosis (ALS) Sales by Country (2021 VS 2025 VS 2032) & (k units) Table 179. Asia Amyotrophic Lateral Sclerosis (ALS) Sales by Country (2021-2026) & (k units) Table 180. Asia Amyotrophic Lateral Sclerosis (ALS) Sales by Country (2027-2032) & (k units) Table 181. Asia Amyotrophic Lateral Sclerosis (ALS) Sales Price by Country (2021-2026) & (US$/unit) Table 182. Asia Amyotrophic Lateral Sclerosis (ALS) Sales Price by Country (2027-2032) & (US$/unit) Table 183. Japan Amyotrophic Lateral Sclerosis (ALS) Revenue (2021-2032) & (US$ Million) Table 184. South Korea Amyotrophic Lateral Sclerosis (ALS) Revenue (2021-2032) & (US$ Million) Table 185. India Amyotrophic Lateral Sclerosis (ALS) Revenue (2021-2032) & (US$ Million) Table 186. Australia Amyotrophic Lateral Sclerosis (ALS) Revenue (2021-2032) & (US$ Million) Table 187. Taiwan Amyotrophic Lateral Sclerosis (ALS) Revenue (2021-2032) & (US$ Million) Table 188. Southeast Asia Amyotrophic Lateral Sclerosis (ALS) Revenue (2021-2032) & (US$ Million) Table 189. SAMEA Amyotrophic Lateral Sclerosis (ALS) Revenue by Type (2021-2026) & (US$ Million) Table 190. SAMEA Amyotrophic Lateral Sclerosis (ALS) Revenue by Type (2027-2032) & (US$ Million) Table 191. SAMEA Amyotrophic Lateral Sclerosis (ALS) Sales by Type (2021-2026) & (k units) Table 192. SAMEA Amyotrophic Lateral Sclerosis (ALS) Sales by Type (2027-2032) & (k units) Table 193. SAMEA Amyotrophic Lateral Sclerosis (ALS) Sales Price by Type (2021-2026) & (US$/unit) Table 194. SAMEA Amyotrophic Lateral Sclerosis (ALS) Sales Price by Type (2027-2032) & (US$/unit) Table 195. SAMEA Amyotrophic Lateral Sclerosis (ALS) Revenue by Application (2021-2026) & (US$ Million) Table 196. SAMEA Amyotrophic Lateral Sclerosis (ALS) Revenue by Application (2027-2032) & (US$ Million) Table 197. SAMEA Amyotrophic Lateral Sclerosis (ALS) Sales by Application (2021-2026) & (k units) Table 198. SAMEA Amyotrophic Lateral Sclerosis (ALS) Sales by Application (2027-2032) & (k units) Table 199. SAMEA Amyotrophic Lateral Sclerosis (ALS) Sales Price by Application (2021-2026) & (US$/unit) Table 200. SAMEA Amyotrophic Lateral Sclerosis (ALS) Sales Price by Application (2027-2032) & (US$/unit) Table 201. SAMEA Amyotrophic Lateral Sclerosis (ALS) Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 202. SAMEA Amyotrophic Lateral Sclerosis (ALS) Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 203. SAMEA Amyotrophic Lateral Sclerosis (ALS) Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 204. SAMEA Amyotrophic Lateral Sclerosis (ALS) Sales by Country (2021 VS 2025 VS 2032) & (k units) Table 205. SAMEA Amyotrophic Lateral Sclerosis (ALS) Sales by Country (2021-2026) & (k units) Table 206. SAMEA Amyotrophic Lateral Sclerosis (ALS) Sales by Country (2027-2032) & (k units) Table 207. SAMEA Amyotrophic Lateral Sclerosis (ALS) Sales Price by Country (2021-2026) & (US$/unit) Table 208. SAMEA Amyotrophic Lateral Sclerosis (ALS) Sales Price by Country (2027-2032) & (US$/unit) Table 209. Brazil Amyotrophic Lateral Sclerosis (ALS) Revenue (2021-2032) & (US$ Million) Table 210. Argentina Amyotrophic Lateral Sclerosis (ALS) Revenue (2021-2032) & (US$ Million) Table 211. Chile Amyotrophic Lateral Sclerosis (ALS) Revenue (2021-2032) & (US$ Million) Table 212. Colombia Amyotrophic Lateral Sclerosis (ALS) Revenue (2021-2032) & (US$ Million) Table 213. Peru Amyotrophic Lateral Sclerosis (ALS) Revenue (2021-2032) & (US$ Million) Table 214. Saudi Arabia Amyotrophic Lateral Sclerosis (ALS) Revenue (2021-2032) & (US$ Million) Table 215. Israel Amyotrophic Lateral Sclerosis (ALS) Revenue (2021-2032) & (US$ Million) Table 216. UAE Amyotrophic Lateral Sclerosis (ALS) Revenue (2021-2032) & (US$ Million) Table 217. Turkey Amyotrophic Lateral Sclerosis (ALS) Revenue (2021-2032) & (US$ Million) Table 218. Iran Amyotrophic Lateral Sclerosis (ALS) Revenue (2021-2032) & (US$ Million) Table 219. Egypt Amyotrophic Lateral Sclerosis (ALS) Revenue (2021-2032) & (US$ Million) Table 220. Key Raw Materials Table 221. Raw Materials Key Suppliers Table 222. Amyotrophic Lateral Sclerosis (ALS) Distributors List Table 223. Amyotrophic Lateral Sclerosis (ALS) Customers List Table 224. Research Programs/Design for This Report Table 225. Authors List of This Report Table 226. Secondary Sources Table 227. Primary Sources List of Figures Figure 1. Amyotrophic Lateral Sclerosis (ALS) Image Figure 2. Global Amyotrophic Lateral Sclerosis (ALS) Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Amyotrophic Lateral Sclerosis (ALS) Market Size Share 2021 VS 2025 VS 2032 Figure 4. Riluzole Image Figure 5. Edaravone (Radicava) Image Figure 6. Other Image Figure 7. Global Amyotrophic Lateral Sclerosis (ALS) Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 8. Global Amyotrophic Lateral Sclerosis (ALS) Market Size Share 2021 VS 2025 VS 2032 Figure 9. Hospital Image Figure 10. Drugs Store Image Figure 11. Other Image Figure 12. Global Amyotrophic Lateral Sclerosis (ALS) Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 13. Global Amyotrophic Lateral Sclerosis (ALS) Revenue (2021-2032) & (US$ Million) Figure 14. Global Amyotrophic Lateral Sclerosis (ALS) Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 15. Global Amyotrophic Lateral Sclerosis (ALS) Revenue Market Share by Region: 2025 Versus 2032 Figure 16. Global Amyotrophic Lateral Sclerosis (ALS) Revenue Market Share by Region (2021-2032) Figure 17. Global Amyotrophic Lateral Sclerosis (ALS) Sales (2021-2032) & (k units) Figure 18. Global Amyotrophic Lateral Sclerosis (ALS) Sales by Region: 2021 VS 2025 VS 2032 (k units) Figure 19. Global Amyotrophic Lateral Sclerosis (ALS) Sales Market Share by Region (2021-2032) Figure 20. US & Canada & Mexico Amyotrophic Lateral Sclerosis (ALS) Sales YoY (2021-2032) & (k units) Figure 21. Europe Amyotrophic Lateral Sclerosis (ALS) Sales YoY (2021-2032) & (k units) Figure 22. China Amyotrophic Lateral Sclerosis (ALS) Sales YoY (2021-2032) & (k units) Figure 23. Asia (Excluding China) Amyotrophic Lateral Sclerosis (ALS) Sales YoY (2021-2032) & (k units) Figure 24. South America, Middle East and Africa Amyotrophic Lateral Sclerosis (ALS) Sales YoY (2021-2032) & (k units) Figure 25. Global Amyotrophic Lateral Sclerosis (ALS) Manufacturers Revenue Share Top 10 and Top 5 in 2025 Figure 26. Global Amyotrophic Lateral Sclerosis (ALS) Manufacturers Sales Share Top 10 and Top 5 in 2025 Figure 27. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 28. Global Amyotrophic Lateral Sclerosis (ALS) Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 29. Global Amyotrophic Lateral Sclerosis (ALS) Revenue Market Share by Type 2021 VS 2025 VS 2032 Figure 30. Global Amyotrophic Lateral Sclerosis (ALS) Revenue Market Share by Type (2021-2032) Figure 31. Global Amyotrophic Lateral Sclerosis (ALS) Sales by Type (2021 VS 2025 VS 2032) & (k units) Figure 32. Global Amyotrophic Lateral Sclerosis (ALS) Sales Market Share by Type 2021 VS 2025 VS 2032 Figure 33. Global Amyotrophic Lateral Sclerosis (ALS) Sales Market Share by Type (2021-2032) Figure 34. Global Amyotrophic Lateral Sclerosis (ALS) Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 35. Global Amyotrophic Lateral Sclerosis (ALS) Revenue Market Share by Application 2021 VS 2025 VS 2032 Figure 36. Global Amyotrophic Lateral Sclerosis (ALS) Revenue Market Share by Application (2021-2032) Figure 37. Global Amyotrophic Lateral Sclerosis (ALS) Sales by Application (2021 VS 2025 VS 2032) & (k units) Figure 38. Global Amyotrophic Lateral Sclerosis (ALS) Sales Market Share by Application 2021 VS 2025 VS 2032 Figure 39. Global Amyotrophic Lateral Sclerosis (ALS) Sales Market Share by Application (2021-2032) Figure 40. North America Amyotrophic Lateral Sclerosis (ALS) Revenue Share by Type (2021-2032) Figure 41. North America Amyotrophic Lateral Sclerosis (ALS) Sales Share by Type (2021-2032) Figure 42. North America Amyotrophic Lateral Sclerosis (ALS) Revenue Share by Application (2021-2032) Figure 43. North America Amyotrophic Lateral Sclerosis (ALS) Sales Share by Application (2021-2032) Figure 44. North America Amyotrophic Lateral Sclerosis (ALS) Revenue Share by Country (2021-2032) Figure 45. North America Amyotrophic Lateral Sclerosis (ALS) Sales Share by Country (2021-2032) Figure 46. Europe Amyotrophic Lateral Sclerosis (ALS) Revenue Share by Type (2021-2032) Figure 47. Europe Amyotrophic Lateral Sclerosis (ALS) Sales Share by Type (2021-2032) Figure 48. Europe Amyotrophic Lateral Sclerosis (ALS) Revenue Share by Application (2021-2032) Figure 49. Europe Amyotrophic Lateral Sclerosis (ALS) Sales Share by Application (2021-2032) Figure 50. Europe Amyotrophic Lateral Sclerosis (ALS) Revenue Share by Country (2021-2032) Figure 51. Europe Amyotrophic Lateral Sclerosis (ALS) Sales Share by Country (2021-2032) Figure 52. China Amyotrophic Lateral Sclerosis (ALS) Revenue Share by Type (2021-2032) Figure 53. China Amyotrophic Lateral Sclerosis (ALS) Sales Share by Type (2021-2032) Figure 54. China Amyotrophic Lateral Sclerosis (ALS) Revenue Share by Application (2021-2032) Figure 55. China Amyotrophic Lateral Sclerosis (ALS) Sales Share by Application (2021-2032) Figure 56. Asia Amyotrophic Lateral Sclerosis (ALS) Revenue Share by Type (2021-2032) Figure 57. Asia Amyotrophic Lateral Sclerosis (ALS) Sales Share by Type (2021-2032) Figure 58. Asia Amyotrophic Lateral Sclerosis (ALS) Revenue Share by Application (2021-2032) Figure 59. Asia Amyotrophic Lateral Sclerosis (ALS) Sales Share by Application (2021-2032) Figure 60. Asia Amyotrophic Lateral Sclerosis (ALS) Revenue Share by Country (2021-2032) Figure 61. Asia Amyotrophic Lateral Sclerosis (ALS) Sales Share by Country (2021-2032) Figure 62. SAMEA Amyotrophic Lateral Sclerosis (ALS) Revenue Share by Type (2021-2032) Figure 63. SAMEA Amyotrophic Lateral Sclerosis (ALS) Sales Share by Type (2021-2032) Figure 64. SAMEA Amyotrophic Lateral Sclerosis (ALS) Revenue Share by Application (2021-2032) Figure 65. SAMEA Amyotrophic Lateral Sclerosis (ALS) Sales Share by Application (2021-2032) Figure 66. SAMEA Amyotrophic Lateral Sclerosis (ALS) Revenue Share by Country (2021-2032) Figure 67. SAMEA Amyotrophic Lateral Sclerosis (ALS) Sales Share by Country (2021-2032) Figure 68. Amyotrophic Lateral Sclerosis (ALS) Value Chain Figure 69. Manufacturing Cost Structure Figure 70. Amyotrophic Lateral Sclerosis (ALS) Production Mode & Process Figure 71. Direct Comparison with Distribution Share Figure 72. Distributors Profiles Figure 73. Years Considered Figure 74. Research Process Figure 75. Key Executives Interviewed

Scope & coverage.

Types
  • Riluzole
  • Edaravone (Radicava)
  • Other
Applications
  • Hospital
  • Drugs Store
  • Other
Companies covered
  • Sun Pharma
  • Sanofi
  • Lunan Pharma
  • Mylan Pharma
  • Mitsubishi Tanabe Pharma
  • Glemark Generics
  • Covis Pharma
  • Apotex

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Amyotrophic Lateral Sclerosis (ALS) Market by Type
  3. 1.2.1 Global Amyotrophic Lateral Sclerosis (ALS) Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Riluzole
  5. 1.2.3 Edaravone (Radicava)
  6. 1.2.4 Other
  7. 1.3 Amyotrophic Lateral Sclerosis (ALS) Market by Application
  8. 1.3.1 Global Amyotrophic Lateral Sclerosis (ALS) Market Size by Application, 2021 VS 2025 VS 2032
  9. 1.3.2 Hospital
  10. 1.3.3 Drugs Store
  11. 1.3.4 Other
  12. 1.4 Assumptions and Limitations
  13. 1.5 Study Goals and Objectives
2 Amyotrophic Lateral Sclerosis (ALS) Market Dynamics
  1. 2.1 Amyotrophic Lateral Sclerosis (ALS) Industry Trends
  2. 2.2 Amyotrophic Lateral Sclerosis (ALS) Industry Drivers
  3. 2.3 Amyotrophic Lateral Sclerosis (ALS) Industry Opportunities and Challenges
  4. 2.4 Amyotrophic Lateral Sclerosis (ALS) Industry Restraints
3 Global Market Growth Prospects
  1. 3.1 Global Amyotrophic Lateral Sclerosis (ALS) Revenue Estimates and Forecasts (2021-2032)
  2. 3.2 Global Amyotrophic Lateral Sclerosis (ALS) Revenue by Region
  3. 3.2.1 Global Amyotrophic Lateral Sclerosis (ALS) Revenue by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Amyotrophic Lateral Sclerosis (ALS) Revenue by Region (2021-2026)
  5. 3.2.3 Global Amyotrophic Lateral Sclerosis (ALS) Revenue by Region (2027-2032)
  6. 3.2.4 Global Amyotrophic Lateral Sclerosis (ALS) Revenue Market Share by Region (2021-2032)
  7. 3.3 Global Amyotrophic Lateral Sclerosis (ALS) Sales Estimates and Forecasts 2021-2032
  8. 3.4 Global Amyotrophic Lateral Sclerosis (ALS) Sales by Region
  9. 3.4.1 Global Amyotrophic Lateral Sclerosis (ALS) Sales by Region: 2021 VS 2025 VS 2032
  10. 3.4.2 Global Amyotrophic Lateral Sclerosis (ALS) Sales by Region (2021-2026)
  11. 3.4.3 Global Amyotrophic Lateral Sclerosis (ALS) Sales by Region (2027-2032)
  12. 3.4.4 Global Amyotrophic Lateral Sclerosis (ALS) Sales Market Share by Region (2021-2032)
  13. 3.5 US & Canada & Mexico
  14. 3.6 Europe
  15. 3.7 China
  16. 3.8 Asia (Excluding China)
  17. 3.9 South America, Middle East and Africa
4 Market Competitive Landscape by Manufacturers
  1. 4.1 Global Amyotrophic Lateral Sclerosis (ALS) Revenue by Manufacturers
  2. 4.1.1 Global Amyotrophic Lateral Sclerosis (ALS) Revenue by Manufacturers (2021-2026)
  3. 4.1.2 Global Amyotrophic Lateral Sclerosis (ALS) Revenue Market Share by Manufacturers (2021-2026)
  4. 4.1.3 Global Amyotrophic Lateral Sclerosis (ALS) Manufacturers Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Amyotrophic Lateral Sclerosis (ALS) Sales by Manufacturers
  6. 4.2.1 Global Amyotrophic Lateral Sclerosis (ALS) Sales by Manufacturers (2021-2026)
  7. 4.2.2 Global Amyotrophic Lateral Sclerosis (ALS) Sales Market Share by Manufacturers (2021-2026)
  8. 4.2.3 Global Amyotrophic Lateral Sclerosis (ALS) Manufacturers Sales Share Top 10 and Top 5 in 2025
  9. 4.3 Global Amyotrophic Lateral Sclerosis (ALS) Sales Price by Manufacturers (2021-2026)
  10. 4.4 Global Amyotrophic Lateral Sclerosis (ALS) Key Manufacturers Ranking, 2024 VS 2025 VS 2026
  11. 4.5 Global Amyotrophic Lateral Sclerosis (ALS) Key Manufacturers Manufacturing Sites & Headquarters
  12. 4.6 Global Amyotrophic Lateral Sclerosis (ALS) Manufacturers, Product Type & Application
  13. 4.7 Global Amyotrophic Lateral Sclerosis (ALS) Manufacturers' Establishment Date
  14. 4.8 Market Competitive Analysis
  15. 4.8.1 Global Amyotrophic Lateral Sclerosis (ALS) Market CR5 and HHI
  16. 4.8.2 2025 Amyotrophic Lateral Sclerosis (ALS) Tier 1, Tier 2, and Tier 3
5 Amyotrophic Lateral Sclerosis (ALS) Market by Type
  1. 5.1 Global Amyotrophic Lateral Sclerosis (ALS) Revenue by Type
  2. 5.1.1 Global Amyotrophic Lateral Sclerosis (ALS) Revenue by Type (2021 VS 2025 VS 2032)
  3. 5.1.2 Global Amyotrophic Lateral Sclerosis (ALS) Revenue by Type (2021-2032) & (US$ Million)
  4. 5.1.3 Global Amyotrophic Lateral Sclerosis (ALS) Revenue Market Share by Type (2021-2032)
  5. 5.2 Global Amyotrophic Lateral Sclerosis (ALS) Sales by Type
  6. 5.2.1 Global Amyotrophic Lateral Sclerosis (ALS) Sales by Type (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Amyotrophic Lateral Sclerosis (ALS) Sales by Type (2021-2032) & (k units)
  8. 5.2.3 Global Amyotrophic Lateral Sclerosis (ALS) Sales Market Share by Type (2021-2032)
  9. 5.3 Global Amyotrophic Lateral Sclerosis (ALS) Price by Type
6 Amyotrophic Lateral Sclerosis (ALS) Market by Application
  1. 6.1 Global Amyotrophic Lateral Sclerosis (ALS) Revenue by Application
  2. 6.1.1 Global Amyotrophic Lateral Sclerosis (ALS) Revenue by Application (2021 VS 2025 VS 2032)
  3. 6.1.2 Global Amyotrophic Lateral Sclerosis (ALS) Revenue by Application (2021-2032) & (US$ Million)
  4. 6.1.3 Global Amyotrophic Lateral Sclerosis (ALS) Revenue Market Share by Application (2021-2032)
  5. 6.2 Global Amyotrophic Lateral Sclerosis (ALS) Sales by Application
  6. 6.2.1 Global Amyotrophic Lateral Sclerosis (ALS) Sales by Application (2021 VS 2025 VS 2032)
  7. 6.2.2 Global Amyotrophic Lateral Sclerosis (ALS) Sales by Application (2021-2032) & (k units)
  8. 6.2.3 Global Amyotrophic Lateral Sclerosis (ALS) Sales Market Share by Application (2021-2032)
  9. 6.3 Global Amyotrophic Lateral Sclerosis (ALS) Price by Application
7 Company Profiles
  1. 7.1 Sun Pharma
  2. 7.1.1 Sun Pharma Company Information
  3. 7.1.2 Sun Pharma Business Overview
  4. 7.1.3 Sun Pharma Amyotrophic Lateral Sclerosis (ALS) Sales, Revenue, Price and Gross Margin (2021-2026)
  5. 7.1.4 Sun Pharma Amyotrophic Lateral Sclerosis (ALS) Product Portfolio
  6. 7.1.5 Sun Pharma Recent Developments
  7. 7.2 Sanofi
  8. 7.2.1 Sanofi Company Information
  9. 7.2.2 Sanofi Business Overview
  10. 7.2.3 Sanofi Amyotrophic Lateral Sclerosis (ALS) Sales, Revenue, Price and Gross Margin (2021-2026)
  11. 7.2.4 Sanofi Amyotrophic Lateral Sclerosis (ALS) Product Portfolio
  12. 7.2.5 Sanofi Recent Developments
  13. 7.3 Lunan Pharma
  14. 7.3.1 Lunan Pharma Company Information
  15. 7.3.2 Lunan Pharma Business Overview
  16. 7.3.3 Lunan Pharma Amyotrophic Lateral Sclerosis (ALS) Sales, Revenue, Price and Gross Margin (2021-2026)
  17. 7.3.4 Lunan Pharma Amyotrophic Lateral Sclerosis (ALS) Product Portfolio
  18. 7.3.5 Lunan Pharma Recent Developments
  19. 7.4 Mylan Pharma
  20. 7.4.1 Mylan Pharma Company Information
  21. 7.4.2 Mylan Pharma Business Overview
  22. 7.4.3 Mylan Pharma Amyotrophic Lateral Sclerosis (ALS) Sales, Revenue, Price and Gross Margin (2021-2026)
  23. 7.4.4 Mylan Pharma Amyotrophic Lateral Sclerosis (ALS) Product Portfolio
  24. 7.4.5 Mylan Pharma Recent Developments
  25. 7.5 Mitsubishi Tanabe Pharma
  26. 7.5.1 Mitsubishi Tanabe Pharma Company Information
  27. 7.5.2 Mitsubishi Tanabe Pharma Business Overview
  28. 7.5.3 Mitsubishi Tanabe Pharma Amyotrophic Lateral Sclerosis (ALS) Sales, Revenue, Price and Gross Margin (2021-2026)
  29. 7.5.4 Mitsubishi Tanabe Pharma Amyotrophic Lateral Sclerosis (ALS) Product Portfolio
  30. 7.5.5 Mitsubishi Tanabe Pharma Recent Developments
  31. 7.6 Glemark Generics
  32. 7.6.1 Glemark Generics Company Information
  33. 7.6.2 Glemark Generics Business Overview
  34. 7.6.3 Glemark Generics Amyotrophic Lateral Sclerosis (ALS) Sales, Revenue, Price and Gross Margin (2021-2026)
  35. 7.6.4 Glemark Generics Amyotrophic Lateral Sclerosis (ALS) Product Portfolio
  36. 7.6.5 Glemark Generics Recent Developments
  37. 7.7 Covis Pharma
  38. 7.7.1 Covis Pharma Company Information
  39. 7.7.2 Covis Pharma Business Overview
  40. 7.7.3 Covis Pharma Amyotrophic Lateral Sclerosis (ALS) Sales, Revenue, Price and Gross Margin (2021-2026)
  41. 7.7.4 Covis Pharma Amyotrophic Lateral Sclerosis (ALS) Product Portfolio
  42. 7.7.5 Covis Pharma Recent Developments
  43. 7.8 Apotex
  44. 7.8.1 Apotex Company Information
  45. 7.8.2 Apotex Business Overview
  46. 7.8.3 Apotex Amyotrophic Lateral Sclerosis (ALS) Sales, Revenue, Price and Gross Margin (2021-2026)
  47. 7.8.4 Apotex Amyotrophic Lateral Sclerosis (ALS) Product Portfolio
  48. 7.8.5 Apotex Recent Developments
8 North America
  1. 8.1 North America Amyotrophic Lateral Sclerosis (ALS) Market Size by Type
  2. 8.1.1 North America Amyotrophic Lateral Sclerosis (ALS) Revenue by Type (2021-2032)
  3. 8.1.2 North America Amyotrophic Lateral Sclerosis (ALS) Sales by Type (2021-2032)
  4. 8.1.3 North America Amyotrophic Lateral Sclerosis (ALS) Price by Type (2021-2032)
  5. 8.2 North America Amyotrophic Lateral Sclerosis (ALS) Market Size by Application
  6. 8.2.1 North America Amyotrophic Lateral Sclerosis (ALS) Revenue by Application (2021-2032)
  7. 8.2.2 North America Amyotrophic Lateral Sclerosis (ALS) Sales by Application (2021-2032)
  8. 8.2.3 North America Amyotrophic Lateral Sclerosis (ALS) Price by Application (2021-2032)
  9. 8.3 North America Amyotrophic Lateral Sclerosis (ALS) Market Size by Country
  10. 8.3.1 North America Amyotrophic Lateral Sclerosis (ALS) Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 8.3.2 North America Amyotrophic Lateral Sclerosis (ALS) Sales by Country (2021 VS 2025 VS 2032)
  12. 8.3.3 North America Amyotrophic Lateral Sclerosis (ALS) Price by Country (2021-2032)
  13. 8.3.4 United States
  14. 8.3.5 Canada
  15. 8.3.6 Mexico
9 Europe
  1. 9.1 Europe Amyotrophic Lateral Sclerosis (ALS) Market Size by Type
  2. 9.1.1 Europe Amyotrophic Lateral Sclerosis (ALS) Revenue by Type (2021-2032)
  3. 9.1.2 Europe Amyotrophic Lateral Sclerosis (ALS) Sales by Type (2021-2032)
  4. 9.1.3 Europe Amyotrophic Lateral Sclerosis (ALS) Price by Type (2021-2032)
  5. 9.2 Europe Amyotrophic Lateral Sclerosis (ALS) Market Size by Application
  6. 9.2.1 Europe Amyotrophic Lateral Sclerosis (ALS) Revenue by Application (2021-2032)
  7. 9.2.2 Europe Amyotrophic Lateral Sclerosis (ALS) Sales by Application (2021-2032)
  8. 9.2.3 Europe Amyotrophic Lateral Sclerosis (ALS) Price by Application (2021-2032)
  9. 9.3 Europe Amyotrophic Lateral Sclerosis (ALS) Market Size by Country
  10. 9.3.1 Europe Amyotrophic Lateral Sclerosis (ALS) Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 9.3.2 Europe Amyotrophic Lateral Sclerosis (ALS) Sales by Country (2021 VS 2025 VS 2032)
  12. 9.3.3 Europe Amyotrophic Lateral Sclerosis (ALS) Price by Country (2021-2032)
  13. 9.3.4 Germany
  14. 9.3.5 France
  15. 9.3.6 U.K.
  16. 9.3.7 Italy
  17. 9.3.8 Russia
  18. 9.3.9 Spain
  19. 9.3.10 Netherlands
10 China
  1. 10.1 China Amyotrophic Lateral Sclerosis (ALS) Market Size by Type
  2. 10.1.1 China Amyotrophic Lateral Sclerosis (ALS) Revenue by Type (2021-2032)
  3. 10.1.2 China Amyotrophic Lateral Sclerosis (ALS) Sales by Type (2021-2032)
  4. 10.1.3 China Amyotrophic Lateral Sclerosis (ALS) Price by Type (2021-2032)
  5. 10.2 China Amyotrophic Lateral Sclerosis (ALS) Market Size by Application
  6. 10.2.1 China Amyotrophic Lateral Sclerosis (ALS) Revenue by Application (2021-2032)
  7. 10.2.2 China Amyotrophic Lateral Sclerosis (ALS) Sales by Application (2021-2032)
  8. 10.2.3 China Amyotrophic Lateral Sclerosis (ALS) Price by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Amyotrophic Lateral Sclerosis (ALS) Market Size by Type
  2. 11.1.1 Asia Amyotrophic Lateral Sclerosis (ALS) Revenue by Type (2021-2032)
  3. 11.1.2 Asia Amyotrophic Lateral Sclerosis (ALS) Sales by Type (2021-2032)
  4. 11.1.3 Asia Amyotrophic Lateral Sclerosis (ALS) Price by Type (2021-2032)
  5. 11.2 Asia Amyotrophic Lateral Sclerosis (ALS) Market Size by Application
  6. 11.2.1 Asia Amyotrophic Lateral Sclerosis (ALS) Revenue by Application (2021-2032)
  7. 11.2.2 Asia Amyotrophic Lateral Sclerosis (ALS) Sales by Application (2021-2032)
  8. 11.2.3 Asia Amyotrophic Lateral Sclerosis (ALS) Price by Application (2021-2032)
  9. 11.3 Asia Amyotrophic Lateral Sclerosis (ALS) Market Size by Country
  10. 11.3.1 Asia Amyotrophic Lateral Sclerosis (ALS) Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 11.3.2 Asia Amyotrophic Lateral Sclerosis (ALS) Sales by Country (2021 VS 2025 VS 2032)
  12. 11.3.3 Asia Amyotrophic Lateral Sclerosis (ALS) Price by Country (2021-2032)
  13. 11.3.4 Japan
  14. 11.3.5 South Korea
  15. 11.3.6 India
  16. 11.3.7 Australia
  17. 11.3.8 Taiwan
  18. 11.3.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Amyotrophic Lateral Sclerosis (ALS) Market Size by Type
  2. 12.1.1 SAMEA Amyotrophic Lateral Sclerosis (ALS) Revenue by Type (2021-2032)
  3. 12.1.2 SAMEA Amyotrophic Lateral Sclerosis (ALS) Sales by Type (2021-2032)
  4. 12.1.3 SAMEA Amyotrophic Lateral Sclerosis (ALS) Price by Type (2021-2032)
  5. 12.2 SAMEA Amyotrophic Lateral Sclerosis (ALS) Market Size by Application
  6. 12.2.1 SAMEA Amyotrophic Lateral Sclerosis (ALS) Revenue by Application (2021-2032)
  7. 12.2.2 SAMEA Amyotrophic Lateral Sclerosis (ALS) Sales by Application (2021-2032)
  8. 12.2.3 SAMEA Amyotrophic Lateral Sclerosis (ALS) Price by Application (2021-2032)
  9. 12.3 SAMEA Amyotrophic Lateral Sclerosis (ALS) Market Size by Country
  10. 12.3.1 SAMEA Amyotrophic Lateral Sclerosis (ALS) Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 12.3.2 SAMEA Amyotrophic Lateral Sclerosis (ALS) Sales by Country (2021 VS 2025 VS 2032)
  12. 12.3.3 SAMEA Amyotrophic Lateral Sclerosis (ALS) Price by Country (2021-2032)
  13. 12.3.4 Brazil
  14. 12.3.5 Argentina
  15. 12.3.6 Chile
  16. 12.3.7 Colombia
  17. 12.3.8 Peru
  18. 12.3.9 Saudi Arabia
  19. 12.3.10 Israel
  20. 12.3.11 UAE
  21. 12.3.12 Turkey
  22. 12.3.13 Iran
  23. 12.3.14 Egypt
13 Value Chain and Sales Channels Analysis
  1. 13.1 Amyotrophic Lateral Sclerosis (ALS) Value Chain Analysis
  2. 13.1.1 Amyotrophic Lateral Sclerosis (ALS) Key Raw Materials
  3. 13.1.2 Raw Materials Key Suppliers
  4. 13.1.3 Manufacturing Cost Structure
  5. 13.1.4 Amyotrophic Lateral Sclerosis (ALS) Production Mode & Process
  6. 13.2 Amyotrophic Lateral Sclerosis (ALS) Sales Channels Analysis
  7. 13.2.1 Direct Comparison with Distribution Share
  8. 13.2.2 Amyotrophic Lateral Sclerosis (ALS) Distributors
  9. 13.2.3 Amyotrophic Lateral Sclerosis (ALS) Customers
14 Concluding Insights
    15 Appendix
    1. 15.1 Reasons for Doing This Study
    2. 15.2 Research Methodology
    3. 15.3 Research Process
    4. 15.4 Authors List of This Report
    5. 15.5 Data Source
    6. 15.5.1 Secondary Sources
    7. 15.5.2 Primary Sources
    8. 15.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst